viewSDX Energy Inc

SDX Energy sells non-core asset for US$3mln as portfolio management effort continues

“This deal demonstrates our continued focus on portfolio and capital management," said chief executive Mark Reid

SDX Energy Inc - SDX Energy sells non-core asset for US$3mln

SDX Energy PLC (LON:SDX) told investors it has sold a non-core asset in the Eastern Desert of Egypt in a deal worth US$3mln.

The group said it has sold a 50% working interest in the North West Gemsa licence to Gulf Energy, a private Egyptian company.

Some US$1.4mln of the proceeds are being immediately used to discharge the company’s remaining liabilities on the licence.

READ: SDX eyes catalysts in Egypt and Morocco

The company pointed out that the deal is part of an ongoing focus and commitment to capital discipline and careful portfolio management.

“We are pleased to complete the sale of our interest in the North West Gemsa licence,” Mark Reid, SDX chief executive said in a statement.

“Whilst we have presented our interest in the licence as non-core for some time, owing to its reducing production and marginal netbacks, it is a welcome outcome to be exiting the licence with a useful cash consideration and also avoiding the upcoming associated budgeted capex of approximately US$2mln for the year.

“This deal demonstrates our continued focus on portfolio and capital management, and we look forward to recycling the cash into projects that will further enhance and grow our business in the future.”

Quick facts: SDX Energy Inc

Price: 17.735 GBX

Market: AIM
Market Cap: £36.42 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SDX Energy Inc named herein, including the promotion by the Company of SDX Energy Inc in any Content on the Site, the Company receives from...



Morning Report: FTSE 100 on back foot over fears it could take years to find...

Headlines from the Proactive UK newsroom. The FTSE 100 is on the back foot on fears it might take years to find an effective vaccine or treatment against coronavirus. The blue-chip index dropped 70 points to 5,755. Overnight, US firm Gilead Sciences terminated a highly anticipated Chinese...

on 24/4/20

2 min read